Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Healthcare Biotechnology
Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Sona Nanotech Inc > Something doesn't add up
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1207)
•••
Comment by Moemoney42on Oct 23, 2020 12:10pm
118 Views
Post# 31771110

RE:RE:RE:Something doesn't add up

RE:RE:RE:Something doesn't add up

To all who think FDA validation is key to unlimited share price growth I'd like you to look at Gilead's chart.. sure they got a spike today but are giving most of it back... and this is for a treatment which is crutial to moving ahead and dealing with covid.. pay attention to reality folks and not pumpers that predict $100, $500 or $1000 share prices..!!

U.S. Food and Drug Administration Approves Gilead ’s Antiviral Veklury ® (remdesivir) for Treatment of COVID-19

 

2020-10-22 16:02 ET - News Releas

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities